Stiamo riscontrando alcuni problemi temporanei. Al momento i dati di mercato in questa pagina sono in ritardo. Attendi mentre risolviamo tale problema e ripristiniamo i tuoi elenchi personalizzati.
FTSE MIB
35.016,50 +200,59 (+0,58%) Dow Jones
39.431,51 -81,29 (-0,21%) Nasdaq
16.388,24 +47,34 (+0,29%) Nikkei 225
38.356,06 +176,60 (+0,46%) Petrolio
78,91 -0,21 (-0,27%) Bitcoin EUR
57.214,25 -832,32 (-1,43%)
Calendari finanziari - Yahoo Finanza
Prec.
- 12magdom
- 13maglun40 Annunci sugli utili13 Frazionamenti azionari3 Prezzi IPO
- 14magmar180 Annunci sugli utili25 Frazionamenti azionari4 Prezzi IPO8 Eventi
- 15magmer189 Annunci sugli utili9 Frazionamenti azionari5 Prezzi IPO36 Eventi
- 16maggio88 Annunci sugli utili17 Frazionamenti azionari1 Prezzi IPO19 Eventi
- 17magven28 Annunci sugli utili17 Frazionamenti azionari1 Prezzi IPO1 Eventi
- 18magsab
Succ.
Yahoo FinanceGameStop stock gains more than 100% as meme-stock market returns with a vengeance
GameStop stock stock surged again early Tuesday, adding to a 74% rise on Monday as meme stocks appear to be back in vogue.
PR NewswireBrex Named #4 on the 2024 CNBC Disruptor 50
Brex, the AI-powered spend platform for modern companies, today announced it has earned the No. 4 ranking on the 2024 CNBC Disruptor 50 list.
PR NewswireLOGISTEC NAMED ONE OF CANADA'S BEST MANAGED COMPANIES
LOGISTEC Corporation ("LOGISTEC"), a leading marine and environmental services provider, has received the 2024 Canada's Best Managed Companies award, now for the second year. This award recognizes LOGISTEC's outstanding business performance, continuous sustained growth, bold strategy, and culture of innovation.
GlobeNewswireAvicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™ in Colombia by INVIMA for Patients with LGS and DS in Colombia. TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived ca
PR NewswireCalliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner Everest Medicines (HKEX: 1952.HK) ("Everest") has launched Nefecon® in China.
Investor's Business DailyAlibaba Stock Slides On Earnings Miss; Sales Increase 7%
Alibaba stock slid in early trading Tuesday, after the Chinese e-commerce giant reported a mixed March-quarter.
GlobeNewswireGlobal Power Rental Market Analysis and Forecasts, 2024-2034: Uninterrupted Power Supply and Business Continuity Demands Fueling Adoption
Global Power Rental Market Global Power Rental Market Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global Power Rental Market: Focus on Application, End-use Industry, Fuel Type, Equipment, and Region - Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global power rental market is experiencing significant growth, driven by a multitude of factors and market drivers. In an optimistic scenario, the market is valued at $11.34 billion in 2024 and is pro
GlobeNewswireDSV, 1108 - SHARE BUYBACK IN DSV A/S
Company Announcement No. 1108 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the Europe
- Clinical Trials Arena
AI database to bolster research for GLP1-RAs as precision medicines
Dandelion Health’s AI database can be used as a tool for sponsors to decide which indications to next investigate GLP1-RAs in.
Clinical Trials ArenaKodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
The company aims to finish enrolling subjects in the trial before the end of this year.
